Ocugen, Inc.
OCGNNext catalyst
OCU400 Low Dose
Retinitis Pigmentosa
Get an email about OCGN's next catalysts
Track Ocugen (OCGN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (Phase 2 readout).See the timeline
2 upcoming, 1 past
OCU400 Low Dose Phase 2 Est. Readout
Primary completion for OCU400 Low Dose trial (NCT05203939) in Retinitis Pigmentosa
SourceOCU400 Med Dose Phase 2 Est. Readout
Estimated primary completion for OCU400 Med Dose trial (NCT05203939) in Retinitis Pigmentosa. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
OCU410ST
Stargardt Disease
OCU410
Dry Age-related Macular Degeneration
Brimonidine Tartrate
Dry Eye
Brimonidine Mono Therapy
Dry Eye
OCU400 Med Dose
Retinitis Pigmentosa
OCU400 Second Eye Dosing
Retinitis Pigmentosa
OCU400 High Dose
Retinitis Pigmentosa
Corticosteroid Eye Drop
Dry Eye
OCU400 Low Dose
Retinitis Pigmentosa
Brimonidine
Dry Eye
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
OCU410ST | Phase 3 | Stargardt Disease | - | - |
OCU410 | Phase 3 | Dry Age-related Macular Degeneration | - | - |
Brimonidine Tartrate | Phase 3 | Dry Eye | - | - |
Brimonidine Mono Therapy | Phase 2 | Dry Eye | - | - |
OCU400 Med Dose | Phase 2 | Retinitis Pigmentosa | - | - |
OCU400 Second Eye Dosing | Phase 2 | Retinitis Pigmentosa | - | - |
OCU400 High Dose | Phase 2 | Retinitis Pigmentosa | - | - |
Corticosteroid Eye Drop | Phase 2 | Dry Eye | - | - |
OCU400 Low Dose | Phase 2 | Retinitis Pigmentosa | - | - |
Brimonidine | Phase 2 | Dry Eye | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Ocugen, Inc.'s drug pipeline?→
CatalystAlert tracks 10 drug candidates in Ocugen, Inc.'s (OCGN) pipeline across Phase 3, Phase 2. Its lead program is Brimonidine Tartrate (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Ocugen, Inc.'s next FDA catalyst?→
Ocugen, Inc.'s (OCGN) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track OCGN biotech catalysts?→
Add OCGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ocugen, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.